The authors evaluated the therapeutic efficacy of RC48, alone or in combination with dabrafenib, in BRAF-mutant cutaneous melanoma cell lines and cell-derived xenograft models.
[Cellular & Molecular Biology Letters]
Home Newsletters Dermal Cell News Combined Therapy of Dabrafenib and an Anti-HER2 Antibody–Drug Conjugate for Advanced BRAF-Mutant...
